Physician profile
Sajeev S Kathuria
NPI 1225065873
$1,540.72
in general payments reported to CMS, 2019-2025
14 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $35.01 · 2022: $37.79 · 2023: $15.89 · 2024: $359 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $965.33 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $252.40 | 2024-2025 | Acthar |
| Bausch & Lomb Americas INC. | $216.90 | 2024-2025 | Envista Mx60 Iol, Envista Envy Iol |
| Galderma Laboratories, L.P. | $193.73 | 2019 | |
| Amgen INC. | $176.71 | 2025 | Tepezza |
| Kerecis Limited | $155.73 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Abbvie INC. | $124.99 | 2024 | |
| Depuy Synthes Sales INC. | $122.70 | 2025 | Trumatch |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $94.76 | 2019 | |
| Horizon Therapeutics Plc | $63.43 | 2019-2022 | |
| Genentech USA, INC. | $57.01 | 2019 | |
| Allergan, INC. | $27.85 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.38 | 2022 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Alcon Vision LLC | $15.89 | 2023 | Centurion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajeev Kathuria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.